Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Down 33.0% in February

Alzamend Neuro, Inc. (NASDAQ:ALZN) was the recipient of a large drop in short interest during the month of February. As of February 15th, there was short interest totalling 52,800 shares, a drop of 33.0% from the January 31st total of 78,800 shares. Currently, 1.0% of the company’s shares are short sold. Based on an average trading volume of 355,200 shares, the short-interest ratio is presently 0.1 days.

Analyst Upgrades and Downgrades

Separately, Ascendiant Capital Markets decreased their price target on Alzamend Neuro from $35.00 to $32.00 and set a “buy” rating for the company in a research note on Monday, December 16th.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Alzamend Neuro stock. Geode Capital Management LLC purchased a new stake in Alzamend Neuro, Inc. (NASDAQ:ALZN) during the fourth quarter, according to its most recent filing with the SEC. The firm purchased 33,540 shares of the company’s stock, valued at approximately $39,000. Geode Capital Management LLC owned 0.62% of Alzamend Neuro at the end of the most recent quarter. Institutional investors and hedge funds own 49.61% of the company’s stock.

Alzamend Neuro Stock Performance

ALZN opened at $0.73 on Wednesday. The stock’s fifty day moving average is $1.10 and its two-hundred day moving average is $1.52. Alzamend Neuro has a 52 week low of $0.69 and a 52 week high of $15.06.

Alzamend Neuro (NASDAQ:ALZN) last released its quarterly earnings data on Wednesday, December 11th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($2.38) by $1.98. On average, research analysts anticipate that Alzamend Neuro will post -1.68 EPS for the current year.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.